Apimeds Pharmaceuticals US, Inc.
APUS
$1.63
-$0.15-8.43%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.37M | 1.28M | 1.53M | 1.34M | 914.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.37M | 1.28M | 1.56M | 1.36M | 962.80K |
| Operating Income | -1.37M | -1.28M | -1.56M | -1.36M | -962.80K |
| Income Before Tax | -1.50M | -1.39M | -1.65M | -1.42M | -1.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.50 | -1.39 | -1.65 | -1.42 | -1.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.50M | -1.39M | -1.65M | -1.42M | -1.01M |
| EBIT | -1.37M | -1.28M | -1.56M | -1.36M | -962.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.19 | -0.18 | -0.23 | -0.21 | -0.16 |
| Normalized Basic EPS | -0.12 | -0.11 | -0.14 | -0.13 | -0.10 |
| EPS Diluted | -0.19 | -0.18 | -0.23 | -0.21 | -0.16 |
| Normalized Diluted EPS | -0.12 | -0.11 | -0.14 | -0.13 | -0.10 |
| Average Basic Shares Outstanding | 31.62M | 31.62M | 30.08M | 26.51M | 22.45M |
| Average Diluted Shares Outstanding | 31.62M | 31.62M | 30.08M | 26.51M | 22.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |